Eloxx Pharmaceuticals, Inc.

DB:397 Stock Report

Market Cap: €5.9m

Eloxx Pharmaceuticals Management

Management criteria checks 1/4

Eloxx Pharmaceuticals' CEO is Sumit Aggarwal, appointed in Apr 2021, has a tenure of 1.67 years. total yearly compensation is $5.82M, comprised of 7% salary and 93% bonuses, including company stock and options. directly owns 0.23% of the company’s shares, worth €13.34K. The average tenure of the management team and the board of directors is 1.7 years and 4.6 years respectively.

Key information

Sumit Aggarwal

Chief executive officer

US$5.8m

Total compensation

CEO salary percentage7.0%
CEO tenure1.7yrs
CEO ownership0.2%
Management average tenure1.7yrs
Board average tenure4.6yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Sumit Aggarwal's remuneration changed compared to Eloxx Pharmaceuticals's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2022n/an/a

-US$42m

Jun 30 2022n/an/a

-US$44m

Mar 31 2022n/an/a

-US$70m

Dec 31 2021US$6mUS$408k

-US$67m

Compensation vs Market: Sumit's total compensation ($USD5.82M) is above average for companies of similar size in the German market ($USD418.12K).

Compensation vs Earnings: Insufficient data to compare Sumit's compensation with company performance.

CEO

Sumit Aggarwal (49 yo)

1.7yrs

Tenure

US$5,824,041

Compensation

Mr. Sumit Aggarwal, MBA serves as a Director at Eloxx Pharmaceuticals, Inc. since April 01, 2021. He is the President and Chief Executive Officer of Eloxx Pharmaceuticals, Inc. since April 01, 2021. He ser...

Leadership Team

NamePositionTenureCompensationOwnership
Sumit Aggarwal
President1.7yrsUS$5.82m0.23%
€ 13.3k
Daniel Geffken
Interim CFO1.7yrsUS$130.75k0%
€ 0
Vijay Modur
Head of Research & Development1.7yrsUS$3.39m0.18%
€ 10.5k
Barbara Ryan
Investor Relations Officerno datano datano data
Ali Hariri
Chief Medical Officer1.1yrsno datano data
Matthew Goddeeris
Vice President of Researchno datano datano data

1.7yrs

Average Tenure

54yo

Average Age

Experienced Management: 397's management team is not considered experienced ( 1.7 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Sumit Aggarwal
President1.7yrsUS$5.82m0.23%
€ 13.3k
Tomer Kariv
Independent Chairman6.2yrsUS$66.70k0%
€ 0
Steven Rubin
Independent Director5yrsUS$79.20k0%
€ 0
Alan Walts
Independent Director1.7yrsUS$252.28k0.043%
€ 2.5k
Patrick Flume
Member of Medical Advisory Boardno datano datano data
Noreen Henig
Member of Medical Advisory Boardno datano datano data
David Bedwell
Member of Scientific Advisory Board4.6yrsno datano data
Rachel Green
Member of Scientific Advisory Board4.6yrsno datano data
Sudhir Kumar
Member of Scientific Advisory Board4.6yrsno datano data
Lynne Maquat
Member of Scientific Advisory Board4.6yrsno datano data
Donald Vandevanter
Member of Medical Advisory Boardno datano datano data
Christiane De Boeck
Member of Medical Advisory Boardno datano datano data

4.6yrs

Average Tenure

61yo

Average Age

Experienced Board: 397's board of directors are considered experienced (4.6 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2022/12/11 01:44
End of Day Share Price 2022/12/06 00:00
Earnings2022/09/30
Annual Earnings2021/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Eloxx Pharmaceuticals, Inc. is covered by 8 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Mayank MamtaniB. Riley Securities, Inc.
Arlinda LeeCanaccord Genuity
Andrew FeinH.C. Wainwright & Co.